Vitrafy Life Sciences Limited (ASX:VFY)

Market Cap	89.71M
Revenue (ttm)	-430.19K
Net Income (ttm)	-36.06M
Shares Out	63.85M
EPS (ttm)	-2.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,200
Average Volume	25,355
Open	1.478
Previous Close	1.510
Day's Range	1.478 - 1.478
52-Week Range	1.120 - 2.040
Beta	n/a
RSI	40.99
Earnings Date	Nov 21, 2025

About Vitrafy Life Sciences

Vitrafy Life Sciences Limited provides cryopreservation solutions in Australia. Its cryopreservation technology improves the cell survival of cryopreserved biological materials, such as blood platelets used to treat trauma patients, t cells used in cancer treatments, and animal sperm used in breeding and farming. The company provides smart freezing device, smart thawing device, and LifeChain, a sample quality management software platform, as well as smart blood bag and sperm packaging solution. It serves animal genetics and animal reproduction ...

• Industry: Laboratory Apparatus and Furniture
• Founded: 2017
• Employees: 22
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: VFY

Financial Performance

In 2024, Vitrafy Life Sciences's revenue was 37,166, a decrease of -98.19% compared to the previous year's 2.06 million. Losses were -10.43 million, 33.4% more than in 2023.